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Multhaup. Ferdinand Hucho, honorary chairman of the 
Luzie Fabisch Foundation, stated: ‘Luzie Fabisch donated 
to the Freie Universität Berlin a sizeable sum of money 
and dedicated it to ‘‘Cancer Research and Cellular Biol-
ogy’’. To give the donation maximum impact, the univer-
sity decided to set it aside for young, not yet settled re-
searchers of the Department of Biology, Chemistry and 
Pharmacy, who wish to organize a symposium related to 
their field of research.’ During the meeting, young scien-
tists were given plenty of opportunity to discuss these 
topics with highly recognized researchers in the field, and 
the size of the meeting with approximately 60 partici-
pants, including 15 invited speakers, reflects this. As a 
new feature, 6 young investigators had the opportunity to 
present and discuss their data in short talks integrated in 
the meeting program. Furthermore, young investigators 
presented and extensively discussed their data in the 
poster session. The Verum Foundation, which promotes 
basic research in neurodegenerative diseases, supported 
the young scientists by awarding the best talks and post-
ers of young investigators (Box 1), which had been select-
ed by an independent jury of national and international 
speakers and participants of the meeting.
 Regulated intramembrane proteolysis (RIP) is a cen-
tral cellular event which is of crucial importance for nor-
mal functioning of the immune and nervous system. If 
the tightly regulated RIP process is disturbed, it might be 
associated with diseases, such as leukemia, rheumatoid 
arthritis, cancer, and Alzheimer’s disease. Today, our un-
derstanding of the RIP process is only partial and many 
questions on functional and molecular levels are still 
open. To discuss these scientific issues, scientists from 5 
European countries and Japan met at a symposium for 
RIP in Potsdam, Germany, on October 5–7, 2011. The two 
major aims of the meeting were (1) to give all participants 
the opportunity to present and discuss their current re-
search data on RIP and (2) to build up a network for suc-
cessful cooperation between different groups working on 
RIP. The venue selected by the organizers Daniela Kaden 
and Gerd Multhaup was the Seminaris Seehotel in Pots-
dam, located at the beautiful lake Templin. It was the 7th 
meeting in a row funded by the Luzie Fabisch Foundation 
and a follow-up meeting to the 6th Fabisch Symposium 
for Cancer Research and Molecular Cell Biology – En-
zymes in Physiology and Pathogenesis: Signaling by 
Secretases in 2009 organized by Lisa M. Munter and Gerd 
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 The scientific part was opened by a session on the 
structure and functions of Alzheimer-related proteins. 
Volker Dötsch, from the Goethe University Frankfurt, 
Germany, is a leading researcher in the expression of 
membrane proteins in cell-free systems. Efficient and 
combinatorial labeling of specific amino acids enables 
him to determine highly resolved NMR structures. In 
more detail, he presented data on the structure of the C-
terminal domain of presenilin (PS) which is part of the 
catalytic center of the   -secretase complex. Moving on 
from NMR to X-ray crystallography, Manuel Than from 
the Leibniz Institute for Age Research in Jena, Germany, 
discussed the structural data of the E1 and E2 domains 
of the amyloid precursor protein (APP). Interestingly, 
they found that copper and zinc binding to the E2 do-
main leads to a conformational switch in the protein. As 
the final speaker of the opening session, Jochen Walter 
from the University of Bonn, Germany, discussed the 
cross talk of membrane lipids and Alzheimer-related 
proteins. He reported about glycosphingolipids which 
are glycosylated derivatives of ceramides highly ex-
pressed in neurons. Glycosphingolipids affect the secre-
tion of APP and stabilize the APP C-terminal fragment 
by inhibiting its degradation by a blockage of the au-
tophagy.
 The pioneer in rhomboid research, Matthew Freeman 
from the MRC Laboratory of Molecular Biology in Cam-
bridge, UK, convinced the audience with the concept of 
inactive rhomboid proteases, the so-called iRhoms, 
which may function in the regulation of other active pro-
teases. He stated that pseudoproteases are common and 
dead enzymes are good templates for specific regulators. 
Karina Reiss from the University of Kiel, Germany, a 
leading scientist in the field of the ADAM (a disintegrin 
and metalloproteinase) proteases and inflammation 
found that ADAM10 and ADAM17 are important regula-
tors of interendothelial cell-cell adhesion mediated by 
vascular endothelial cadherin and might thereby affect 
arteriosclerosis. Furthermore and in line with Jochen 
Walter, she demonstrated that the membrane lipid com-
position is important for ADAM regulation and deter-
mines the substrate cleavage. Unsaturated fatty acids re-
sult in more fluidity of the membrane and more efficient 
cleavage. Ana-Nicoleta Bondar from the Department of 
Physics of the Free University of Berlin, Germany, sup-
ported the experimental data on RIP proteases by mo-
lecular dynamics simulations of the rhomboid protease 
GlpG. Consistent with the data presented by Jochen Wal-
ter and Karina Reiss, she nicely illustrated the conforma-
tional dynamics of the substrate-docking site, which is 
largely affected by the presence of specific lipids and the 
substrate. Shedding of the extracellular substrate domain 
to generate short C- or N-terminal fragments is a prereq-
uisite for most RIP proteases. Using the example of SPPL 
(signal peptide peptidase-like proteases) cleavage of the 
foamy virus envelope protein (HFVenv), Regina Fluhrer 
from the Ludwig Maximilians University (LMU) and 
German Center for Neurodegenerative Diseases (DZNE) 
in Munich, Germany, nicely demonstrated in a young in-
vestigator talk that SPPL3 is able to cleave the full-length 
substrate HFVenv and is therefore independent of a pre-
ceding shedding event. Jörg B. Schulz from the RWTH 
Aachen, Germany, presented data on the lifeguard pro-
tein Faim2 (Fas inhibitory molecule). An ischemia mod-
el in mice revealed functions of Faim2 in the protection 
of DD95L/FasL-mediated toxicity. The session was closed 
by an excellent young investigator talk of Lina Fleig from 
the group of Marius Lemberg at the University in Heidel-
berg, Germany. She presented data showing that the in-
tramembrane protease RHBDL4 is upregulated by endo-
plasmic reticulum (ER) unfolded protein response and 
participates in the ER-associated degradation of mem-
 Box 1 
 A jury of eight independent researchers (V. Dötsch, M. 
Freeman, G. Gouras, O. Andersen, S. Weggen, O.Huber, A.-N. 
Bondar, and P. Hildebrand) was asked to vote for the best 
poster and short talks (young investigator talks). Prizes were 
funded by the Verum Foundation and were awarded for the 
best posters to:
 (1) Nina Bergbold, University of Heidelberg, ZMBH, Germa-
ny – The Intramembrane Protease RHBDL4 Facilitates 
Dislocation in Endoplasmic Reticulum-Associated Degra-
dation. 
 (2) Arnela Mehmedbasic, Aarhus University, Denmark – 
 SorLA Glycosylation and Binding to APP. 
 (3) Christian Tackenberg, University of Zürich, Switzer-
land – Neuro- and Synaptotoxicity of Different A  Mu-
tants. 
 For the best short talks, there were three equal prizes given to:
 • Amelie Ebke, LMU and DZNE Munich, Germany – Novel 
  -Secretase Modulators Directly Target Presenilin. 
 • Luise Richter, Free University Berlin, Germany – Small 
Compounds Interfering with APP Transmembrane Se-
quence Dimerization as Promising Therapeutic Agents 
against Alzheimer’s Disease. 
 • Lina Fleig, University of Heidelberg, ZMBH, Germany – 
The Intramembrane Protease RHBDL4 Facilitates Dislo-
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brane proteins. Inactive RHBDL4 leads to ER stress and 
unfolded protein response induction, suggesting that this 
protease plays an important role in the surveillance of ER 
protein folding.
 The afternoon session focused on RIP, gene regulation 
and the trafficking and toxicity of the amyloid-  (A  ) 
peptides. Uwe Konietzko from the Psychiatric University 
Hospital Zürich, Switzerland, reported on the roles of the 
APP protein family in nuclear signaling. He found that 
APP and the amyloid precursor-like protein 2 (APLP2) 
have a higher turnover than APLP1 and that the intracel-
lular domain of APLP1 is not involved in nuclear signal-
ing like the other two family members. In a young inves-
tigator talk, Christian Barucker from the Free University 
Berlin, Germany, described the role of the neurotoxic 
A  42 peptide in nuclear signaling and gene regulation. 
Several publications suggest that the APP intracellular 
domain has gene regulatory functions; however, the 
A  42-mediated gene regulation is novel and unique, as 
other nontoxic A  peptides (A  38, A  40, or A  42 G33A) 
translocate to the nucleus, but do not affect gene regula-
tion. In line with a proposed intracellular A  function or 
dysfunction, Gunnar Gouras from the Lund University 
in Sweden discussed novel data on the intraneuronal ac-
cumulation of A  , which occurs a long time before extra-
cellular amyloid plaques appear.
 Roland Brandt and the young investigator Lidia Ba-
kota from the University of Osnabrück, Germany, dis-
cussed the relationship of tau and A  toxicity in ex vivo 
and in vitro models. They found that A  fragments (3–
42) induce a specific retention of tau in axons and den-
drites. However, at moderate A  concentrations the pres-
ence of tau does not promote degeneration. Moreover, 
moderate concentrations of A  physiologically modulate 
synaptic connectivity in vivo. 
 As special guest from Tokyo, Japan, Taisuke Tomita 
gave a detailed overview about novel inspiring findings 
on the modulation of   - and   -secretase activity. On the 
one hand, he found that sphingosin-1-phosphate (S1P) 
specifically binds to the   -site APP-cleaving enzyme 1 
(BACE1) and increases its proteolytic activity, suggesting 
that cellular S1P directly modulates BACE1 activity and 
provides therefore a novel potential therapeutic target for 
Alzheimer’s disease. On the other hand, he showed by 
photolabeling experiments that the   -secretase modula-
tor 1 (GSM1) directly targets the transmembrane domain 
1 of PS1, thereby affecting the structure of the initial sub-
strate binding and the catalytic sites of the   -secretase. 
 Gerd Multhaup continued the session with the de-
scription of a novel putative role of BACE1 in copper 
transport. Copper stabilizes BACE1 dimers via a cysteine 
residue in the transmembrane sequence (TMS) and influ-
ences secretion of soluble APP  . Another function of 
BACE1 was demonstrated in a young investigator talk by 
Manuel Gersbacher from the group of Dora Kovacs at the 
Massachusetts General Hospital, USA. He reported that 
BACE1 activity controls voltage-gated sodium channel 
levels (Nav1.1) under physiological conditions. Nav1.1 
protein and mRNA levels are regulated by successive   - 
and   -secretase cleavage of the voltage-gated sodium 
channel   2 subunit (Nav  2). Thus, one needs to keep in 
mind that BACE1 inhibition as a therapeutic target for 
Alzheimer’s disease may affect Nav1.1 metabolism and 
alter neuronal membrane excitability. To map novel 
physiological BACE1 substrates, Stefan Lichtenthaler 
from the LMU and DZNE in Munich, Germany, devel-
oped the method of secretome protein enrichment with 
click sugars. By using this method he is able to specifi-
cally label glycosylated soluble proteins whereas enrich-
ment of serum proteins is reduced by a factor of 100. By 
using specific inhibitors, he could also quantify the rate 
of BACE1 cleavage over other sheddases such as the   -
secretases, e.g. ADAM proteases. The session was closed 
by Lisa M. Munter from the Free University Berlin, Ger-
many, with the finding that mutations around the   -
secretase cleavage site may also affect the   -secretase 
cleavage. In turn, certain mutations around the   -secre-
tase cleavage site in the TMS enhanced or decreased shed-
ding by BACE1 to produce sAPP  .
 The final session dealt with the controversial issue of 
  -secretase modulators (GSMs). The central question 
which arises is whether GSMs bind to the APP-TMS and 
A  or to the PS1 NTF. But first, Johan Lundkvist from 
AstraZenecka, Sweden, presented data on a novel method 
to quanify tri- and tetrapeptides generated by sequential 
  -secretase cleavages. However, he also reported about al-
ternative cleavages and less frequently generated tripep-
tides. He introduced novel nonacidic GSMs which differ-
entially affect the generation of shorter A  species. In ad-
dition to the binding of GSM1 to the transmembrane 
domain 1 of PS1 as described by T. Tomita, Luise Richter 
a young investigator from the group of Gerd Multhaup at 
the Free University in Berlin, Germany, reported specific 
binding of GSM1 to the A  sequence, decreasing the di-
merization of the APP TMS. Her data indicate that one 
possible mode of GSM action is to vary, e.g. stabilize or 
destabilize, the dimerization strength of the APP TMS. 
The data were supported by structural models envisaged 
by Peter Hildebrand from the Charité Berlin, Germany. 
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mer via   -electron interactions with main-chain atoms 
and van der Waals packing with side chains by means of 
flexible docking. The session and the meeting were closed 
by a young investigator talk of Amelie Ebke from the 
group of Harald Steiner at LMU and DZNE Munich, Ger-
many. By using a photoaffinity-labeling approach she 
demonstrated that novel nonacidic bridged aromatic 
GSMs, developed by F. Hoffmann-La Roche Ltd., specifi-
cally target the PS N-terminal fragments. Further, she 
identified shared and overlapping binding sites with non-
acidic and acidic GSMs, respectively.
 The question of whether GSMs bind to APP or PS is 
still controversial, but the data presented at the meeting 
do not preclude one or the other possibility. Rather, a dual 
mode of action of the acidic GSMs is to be assumed, e.g. 
binding of GSMs to both proteins, the substrate APP and 
the catalytical component PS.
 In summary, the meeting introduced a lot of novel 
concepts and ideas and facilitated extensive discussions 
of the speakers and participants. The organizers are not 
only grateful to the Luzie Fabisch Foundation but also to 
the Verum Foundation (Box 1), the GRK1123, Neurocure 
and the SFB740 for financial support (for more informa-
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